Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor

Arthritis and Rheumatism

Volumn 52, Issue 2, 2005, Pages 451-460

  Mueller, Ruediger B ^a   Skapenko, Alla ^a   Grunke, Mathias ^b   Wendler, Jörg ^c   Stuhlmuller, Bruno ^d   Kalden, Joachim R ^b   Schulze Koops, Hendrik ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Rheumatologische Gemeinschaftspraxis   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CLASS II TRANSACTIVATOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANALYTIC METHOD; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; BONE MARROW CELL; CELL ASSAY; CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MACROPHAGE; MALE; MOLECULE; MONOCYTE; PATIENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 13444311557     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20863     Document Type: Article

References (59)

1. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
2. Brennan FM, Maini RN, Feldmann M. TNF α: a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992;31:293-8.
3. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
5. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992;89:9784-8.
6. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, et al. In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996;156:1646-53.
7. Pisetsky DS. Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 2000;43:2381-2.
8. Charles PJ, Smeenk RJ, de Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
9. De Rycke L, Kruithof E, van Damme N, Hoffman IE, van den Bossche N, van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
10. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus erythematosus and TNF-α blockers [letter]. Lancet 2002;360:646.
11. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, et al. Anti-tumor necrosis factor-α therapy-induced vasculitis: case series. J Rheumatol 2003;30:2287-91.
12. Van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4.
13. Isomaki P, Panesar M, Annenkov A, Clark JM, Foxwell BM, Chernajovsky Y, et al. Prolonged exposure of T cells to TNF down-regulates TCR ζ and expression of the TCR/CD3 complex at the cell surface. J Immunol 2001;166:5495-507.
14. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573-84.
15. Cope AP, Londei M, Chu NR, Cohen SB, Elliott MJ, Brennan FM, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
16. Gordon C, Ranges GE, Greenspan JS, Wofsy D. Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol 1989;52:421-34.
17. Fujii I, Shingu M, Nobunaga M. Monocyte activation in early onset rheumatoid arthritis. Ann Rheum Dis 1990;49:497-503.
18. Schulze-Koops H, Davis LS, Kavanaugh AF, Lipsky PE. Elevated cytokine messenger RNA levels in the peripheral blood of patients with rheumatoid arthritis suggest different degrees of myeloid cell activation. Arthritis Rheum 1997;40:639-47.
19. Panush RS. Monocytes in rheumatoid arthritis: regulatory, effector, and phenotypic properties. J Rheumatol 1985;12:1053-61.
20. Yanni G, Whelan A, Feighery C, Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis 1994;53:39-44.
21. Cutolo M, Sulli A, Barone A, Seriolo B, Accardo S. Macrophages, synovial tissue and rheumatoid arthritis. Clin Exp Rheumatol 1993;11:331-9.
22. Ridley MG, Kingsley G, Pitzalis C, Panayi GS. Monocyte activation in rheumatoid arthritis: evidence for in situ activation and differentiation in joints. Br J Rheumatol 1990;29:84-8.
23. Stuhlmuller B, Ungethum U, Scholze S, Martinez L, Backhaus M, Kraetsch HG, et al. Identification of known and novel genes in activated monocytes from patients with rheumatoid arthritis. Arthritis Rheum 2000;43:775-90.
24. Blom AB, Radstake TR, Holthuysen AE, Sloetjes AW, Pesman GJ, Sweep FG, et al Increased expression of Fcγ receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor α and matrix metalloproteinase. Arthritis Rheum 2003;48:1002-14.
25. Steven MM, Lennie SE, Sturrock RD, Gemmell CG. Enhanced bacterial phagocytosis by peripheral blood monocytes in rheumatoid arthritis. Ann Rheum Dis 1984;43:435-9.
26. Lechler RI, Norcross MA, Germain RN. Qualitative and quantitative studies of antigen-presenting cell function by using I-A-expressing L cells. J Immunol 1985;135:2914-22.
27. Baumgart M, Moos V, Schuhbauer D, Muller B. Differential expression of major histocompatibility complex class II genes on murine macrophages associated with T cell cytokine profile and protective/suppressive effects. Proc Natl Acad Sci U S A 1998;95:6936-40.
28. Romain PL, Schlossman SF, Reinherz EL. Surface molecules involved in self-recognition and T cell activation in the autologous mixed lymphocyte reaction. J Immunol 1984;133:1093-100.
29. Han Y, Zhou ZH, Ransohoff RM. TNF-α suppresses IFN-γ-induced MHC class II expression in HT1080 cells by destabilizing class II trans-activator mRNA. J Immunol 1999;163:1435-40.
30. Kim KA, Kim S, Chang I, Kim GS, Min YK, Lee MK, et al. IFNγ/TNFα synergism in MHC class II induction: effect of nicotinamide on MHC class II expression but not on islet-cell apoptosis. Diabetologia 2002;45:385-93.
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
32. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
33. Rosenberg SA, Lipsky PE. Monocyte dependence of pokeweed mitogen-induced differentiation of immunoglobulin-secreting cells from human peripheral blood mononuclear cells. J Immunol 1979;122:926-31.
34. Eberwine J. Amplification of mRNA populations using aRNA generated from immobilized oligo(dT)-T7 primed cDNA. Biotechniques 1996;20:584-91.
35. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
36. Schulze-Koops H, Lipsky PE, Davis LS. Human memory T cell differentiation into Th2-like effector cells is dependent on IL-4 and CD28 stimulation and inhibited by TCR ligation. Eur J Immunol 1998;28:2517-29.
37. Skapenko A, Lipsky PE, Kraetsch HG, Kalden JR, Schulze-Koops H. Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. J Immunol 2001;166:4283-92.
38. Riley JL, Westerheide SD, Price JA, Brown JA, Boss JM. Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). Immunity 1995;2:533-43.
39. Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H. Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol 1999;163:491-9.
40. Bach EA, Aguet M, Schreiber RD. The IFN γ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91.
41. Becker S. Interferon-γ accelerates immune proliferation via its effect on monocyte HLA-DR expression. Cell Immunol 1985;91:301-7.
42. Dolhain RJ, ter Haar NT, Hoefakker S, Tak PP, de Ley M, Claassen E, et al. Increased expression of interferon (IFN)-γ together with IFN-γ receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br J Rheumatol 1996;35:24-32.
43. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al, and the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
44. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
45. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
46. Grewal IS, Grewal KD, Wong FS, Picarella DE, Janeway CA Jr, Flavell RA. Local expression of transgene encoded TNF α in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J Exp Med 1996;184:1963-74.
47. Jacob CO, Aiso S, Schreiber RD, McDevitt HO. Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int Immunol 1992;4:611-4.
48. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin 1. Proc Natl Acad Sci U S A 1990;87:968-72.
49. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
50. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 1997;3:678-81.
51. Mach B. MHC class II regulation: lessons from a disease. N Engl J Med 1995;332:120-2.
52. Askew D, Burger CJ, Elgert KD. Tumor-induced modulation of macrophage class II MHC molecule mRNA expression. Mol Immunol 1993;30:911-20.
53. Melhus O, Koerner TJ, Adams DO. Effects of TNF α on the expression of class II MHC molecules in macrophages induced by IFN γ: evidence for suppression at the level of transcription. J Leukoc Biol 1991;49:21-8.
54. Girvin AM, Gordon KB, Welch CJ, Clipstone NA, Miller SD. Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood 2002;99:3692-701.
55. Charreau B, Coupel S, Boulday G, Soulillou JP. Cyclosporine inhibits class II major histocompatibility antigen presentation by xenogeneic endothelial cells to human T lymphocytes by altering expression of the class II transcriptional activator gene. Transplantation 2000;70:354-61.
56. Nikcevich KM, Piskurich JF, Hellendall RP, Wang Y, Ting JP. Differential selectivity of CIITA promoter activation by IFN-γ and IRF-1 in astrocytes and macrophages: CIITA promoter activation is not affected by TNF-α. J Neuroimmunol 1999;99:195-204.
57. Dong Y, Rohn WM, Benveniste EN. IFN-γ regulation of the type IV class II transactivator promoter in astrocytes. J Immunol 1999;162:4731-9.
58. Wynn TA, Freund YR, Paulnock DM. TNF-α differentially regulates Ia antigen expression and macrophage tumoricidal activity in two murine macrophage cell lines. Cell Immunol 1992;140:184-96.
59. Watanabe Y, Jacob CO. Regulation of MHC class II antigen expression: opposing effects of tumor necrosis factor-α on IFN-γ-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell. J Immunol 1991;146:899-905.